Tuesday, November 24, 2020

Russia says Sputnik V virus vaccine 92% effective

The vaccine uses modified viruses of the regular flu, with 40,000 volunteers taking part in the final phase of trials.

Other News

FIFA bans head of African football from the game over corruption

CAF paid for Ahmad and other Muslim federation heads to travel to Saudi Arabia for the umrah pilgrimage.

2,188 kes baru Covid-19, 1,623 di Selangor

Angka keseluruhan Covid-19 kini berjumlah 58,847 kes.

New cases soar to 2,188

1,623 cases reported in Selangor.

40 production companies get RM13.9 million from Finas

The funds, from Finas' Digital Content Fund, aim to help strengthen the creative industry affected by the Covid-19 pandemic.

40 syarikat produksi terima dana kandungan digital bernilai RM13.9 juta

DKD bertujuan membantu memperkasakan semula industri kreatif yang terjejas akibat impak pandemik Covid-19.

Russia’s Sputnik V coronavirus vaccine is 92% effective according to initial test results, its developers said on Wednesday, as Moscow races against its competitors in the West.

The calculations were based on results from 16,000 individuals who received both doses of the vaccine, Russia’s health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.

“The Sputnik V vaccine had an efficacy rate of 92% after the second dose,” the statement said, after 20 of the volunteers, some of whom were given the placebo, tested positive for coronavirus.

The adenovirus vector-based vaccine uses modified viruses of the regular flu.

Some of those vaccinated experienced “pain at the injection site, flu-like syndrome including fever, weakness, fatigue and headache,” the statement said.

Russia in August became the first country to register a coronavirus vaccine but did so ahead of the large-scale clinical trials that are still underway.

Forty thousand volunteers at 29 medical centres are taking part in the third and final phase of Sputnik V trials.

In September, the vaccine was separately administered to medics and other at-risk people working in Russian hospitals, demonstrating an efficacy rate of “over 90%,” the statement said.

Regional authorities in Siberia’s Altai region on Tuesday said that at least three medics out of the 42 that received the vaccine had contracted the virus.

Wednesday’s statement added that the interim research data will be published in one of the world’s “leading peer-reviewed medical academic journals”.

Observation of trial participants will continue for six months, after which the full clinical trial report will be presented, it added.

The statement said that RDIF, which is funding development of Sputnik V, will provide research data to countries that are interested in purchasing the Russian vaccine.

Overseas trials are also taking place in the UAE, Venezuela, Belarus and other countries, the statement said.

The announcement of Sputnik V’s interim results comes days after Western vaccine developers Pfizer and BioNTech said that their vaccine was more than 90% effective.

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

New cases soar to 2,188

1,623 cases reported in Selangor.

Vaccines not just for rich countries, says WHO

Wealthy nations are already buying up vaccine supplies, leaving poorer countries potentially empty handed.

Thailand extends emergency for 45 days until mid-January

Thailand's international borders will remain closed to casual travellers.

Record 1,884 new cases, 1,203 in Selangor

Two more deaths take toll to 337.

AstraZeneca, Oxford say Covid vaccine shows 70% efficacy

The 70% average is lower compared with the efficacy of coronavirus vaccines trialled by rivals Pfizer/BioNTech and Moderna which have come in above 90%.